This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Regeneron (REGN) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 56.68% and 28.14%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
CRISPR Therapeutics (CRSP) Q3 Earnings Beat, Revenues Lag
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reports narrower-than-expected Q3 loss. Yet, revenues miss estimates for the third quarter of 2021.
Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Lag
by Zacks Equity Research
Clovis (CLVS) reports wider-than-expected loss for third-quarter 2021. Sales of the company's sole marketed drug, Rubraca, declined year over year owing to COVID-19 impacts.
Agios (AGIO) Reports Narrower-Than-Expected Loss in Q3
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) posts narrower-than-expected loss for the third quarter of 2021. It does not record any revenues in the quarter.
Is Regeneron Pharmaceuticals (REGN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (REGN) Outperforming Other Medical Stocks This Year?
Deciphera (DCPH) Q3 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Deciphera (DCPH) reports wider-than-expected loss and revenue miss in the third quarter. It is gearing up for multiple developments and pipeline updates in the fourth quarter.
Drug, Biotech Stock Q3 Earnings on Nov 4: MRNA, REGN & More
by Zacks Equity Research
Let us take a look at five drug/biotech companies due to release their quarterly results on Nov 4.
Should You Buy Regeneron Pharmaceuticals (REGN) Ahead of Earnings?
by Zacks Equity Research
Regeneron Pharmaceuticals (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Vertex (VRTX) Beats on Q3 Earnings & Sales, Raises '21 View
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) earnings and sales beat estimates for the third quarter of 2021. The company raises its product revenue guidance for the year.
Bausch's (BHC) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) beats on earnings but misses on sales in the third quarter. The company reiterates annual revenue guidance.
Organogenesis (ORGO) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
On Organogenesis' (ORGO) upcoming third-quarter earnings call, investor focus is likely to be on the sales performance of its two segments - advanced wound care, and surgical & sports medicine.
Viatris (VTRS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris' (VTRS) Q3 earnings might have gained from the solid performance of Viagra, Dymista, and the Thrombosis portfolio.
Novavax (NVAX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) upcoming third-quarter earnings call, investor focus is likely to be on the company's progress with its COVID-19 vaccine candidate NVX-CoV2373.
Cassava Sciences (SAVA) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Investors will watch for updates on its lead candidate, sumifilam, for Alzheimer's disease in Cassava's (SAVA) Q3 earnings call.
Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the sales outlook for Moderna's (MRNA) authorized coronavirus vaccine on the third-quarter earnings call.
Will Eylea, Dupixent, REGEN COV Aid Regeneron (REGN) Q3 Earnings?
by Zacks Equity Research
Regeneron's third-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent and incremental contribution from its antibody cocktail.
Will Higher Revenues Boost Motorola's (MSI) Q3 Earnings?
by Zacks Equity Research
Motorola's (MSI) performance in the third quarter of 2021 is likely to have benefited from the increasing demand for its mission-critical technologies in North America and globally.
Blueprint Medicines (BPMC) Misses on Q3 Earnings & Revenues
by Zacks Equity Research
Blueprint Medicines (BPMC) misses earnings and revenue estimates for the third quarter of 2021. Yet, the stock price surges as the company provides encouraging pipeline updates.
Amgen (AMGN) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Volume growth of Amgen's (AMGN) key drugs like Prolia, Kyprolis, Repatha and others and biosimilars portfolio is expected to have been partially offset by biosimilar/generic competition for mature drugs.
4 Big Drug, Biotech Stocks Set to Beat Q3 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.
Repligen (RGEN) Q3 Earnings and Sales Beat, 2021 View Up
by Zacks Equity Research
Repligen's (RGEN) third-quarter earnings and revenues beat estimates. The company raises its guidance for 2021. Resultantly, the stock rises.
Alnylam's (ALNY) Q3 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Alnylam's (ALNY) earnings and sales miss estimates in the third quarter of 2021. The company reiterates its financial guidance for 2021. Stock down.
Zacks.com featured highlights include: Seagate Technology, Best Buy, Celanese, CBRE Group and Regeneron Pharma
by Zacks Equity Research
Zacks.com featured highlights include: Seagate Technology, Best Buy, Celanese, CBRE Group and Regeneron Pharma
Gilead (GILD) Q3 Earnings Beat on Increased Veklury Sales
by Zacks Equity Research
Gilead (GILD) beats on sales and earnings in the third quarter. While the HIV business is affected by the pandemic and generics, Veklury maintains momentum.